Risperidone
- Generic Name
- Risperidone
- Brand Names
- Perseris, Risperdal, Rykindo, Uzedy, Okedi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O2
- CAS Number
- 106266-06-2
- Unique Ingredient Identifier
- L6UH7ZF8HC
- Background
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...
- Indication
Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...
- Associated Conditions
- Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
- Associated Therapies
- -
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 287
- Registration Number
- NCT04512066
- Locations
- 🇺🇸
CNRI - Los Angeles, LLC, Pico Rivera, California, United States
🇺🇸Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States
🇺🇸Uptown Research Institute, Chicago, Illinois, United States
"Extended" (Alternate Day) Antipsychotic Dosing
- Conditions
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 120
- Registration Number
- NCT04478838
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 350
- Registration Number
- NCT04446234
- Locations
- 🇨🇳
CHINA, Shanghai, Minhang, China
Risperidone for the Treatment of Huntington's Disease Involuntary Movements
- Conditions
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 5
- Registration Number
- NCT04201834
- Locations
- 🇺🇸
URMC Neurology; 919 Westfall Rd, Building C, Suite 100, Rochester, New York, United States
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Lone Baandrup
- Target Recruit Count
- 64
- Registration Number
- NCT04105231
- Locations
- 🇩🇰
Center for Neuropsychiatric Schizophrenia Research, Glostrup, Denmark
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT03978832
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Garden Grove, California, United States
Therapeutic Issues for Autism
- Conditions
- Interventions
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Minia University
- Target Recruit Count
- 80
- Registration Number
- NCT03887754
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Fundación Marques de Valdecilla
- Target Recruit Count
- 115
- Registration Number
- NCT03883204
- Locations
- 🇪🇸
University Hospital Marques de Valdecilla, Santander, Cantabria, Spain
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
- Conditions
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 2700
- Registration Number
- NCT03790085
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Calo Psychiatric Center
- Target Recruit Count
- 111
- Registration Number
- NCT03730857
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.